NOVEL DRUG DELIVERY STRATEGIES AND APPROACHES FOR WOUND HEALING MANAGEMENTS
New ideas on controlling the pharmacokinetics, pharmacodynamics, non specific toxicity, immunogenicity, biorecognition and efficiency of drugs have generated new strategies, often called as the drug delivery system. Evolution of an existing drug molecule from a conventional form to a novel delivery system can significantly improve its performance in terms of patient compliance, safety, and efficacy. Over the past several years, great advances have been made on development of novel drug delivery systems (NDDS) from synthetic and natural bioactives such as polymeric nanoparticles, nanocapsules, liposomes, phytosomes, nanoemulsions, microsphere, transferosomes, and ethosomes have been reported. The variety of dressings based on types of wounds and novel polymers used for the delivery of drugs to acute and chronic wound has resulted in a wide range of new products frequently introduced to target different aspects of the wound healing process. These include hydrocolloids, alginates, hydrogels, polyurethane, collagen, chitosan, pectin and hyaluronic acid. Nevertheless, nanofibers with their physicochemical properties and nanotopography display improvements in the fields of tissue engineering, wound therapy and drug delivery systems. At present, there are so many existing drug delivery technologies that a total compilation is not within the scope of this article. Yet an attempt is being made to compile some of the most successfully marketed drug delivery technologies. This review extends the information and hopes to give insight into past, present and future strategies and approaches for wound healing managements.Keywords: Drug delivery systems, Novel drug delivery, Wound, Wound healing management.
2. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based microand nanoparticles in drug delivery. J Control Release 100;5-28:2004.
3. Clark RA. Cutaneous tissue repair: basic biologic considerations. J Am Acad Dermatol 1985;13:701â€“25.
4. Wong DJ, Chang HY. Skin tissue engineering in stembook [Internet]. Cambridge, MA: Harvard Stem Cell Institute; 2008.
5. Jahoda CA, Reynolds AJ. Hair follicle dermal sheath cells: Unsung participants in wound healing. Lancet 2001;358:1445â€“8.
6. Sellheyer K, Krahl D. Skin mesenchymal stem cells: Prospects for clinical dermatology. J Am Acad Dermatol 2010;63:859â€“65.
7. Lazarus GS, Cooper DM, Knighton DR, Margolis DJ, Percoraro ER, Rodeheaver G, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994;130:489-93.
8. Rothe M, Falanga V. Growth factors, their biology and promise in dermatologic diseases and tissue repair. Arch Dermatol 1989;125:1390-8.
9. Shakespeare P. Burn wound healing and skin substitutes. Burns 2001;27:517-22.
10. Schultz GS. Molecular regulations of wound healing. In: Bryant RA. editor. Acute and chronic wounds: Nursing management. 2nd edition. St. Louis, MO: Mosby; 1999. p. 413-29.
11. Cooper DM. Burn wound healing: New standings. Nursing Practice Forum 1999;10:74-86.
12. Evans H. A treatment of last resort. Nursing Times 1997;93:62-5.
13. Moore D. Hypochlorites: A review of the evidence. J Wound Care 1992;1:44-53.
14. Poon VK, Burd A. In vitro cytotoxicity of silver: implication for clinical wound care. Burns 2004;30:140-7.
15. Kotek R. Recent advances in polymer fibers. Polymer Rev 2008;48:221.
16. Knighton DR, Ciresi KF, Fiegel VD. Classification and treatment of chronic non-healing wounds. Ann Surg 1986;204:322.
17. Burd A, Kwok CH, Hung SC, Chan HS, Gu H, Lam WK, et al. A comparative study of the cytotoxicity of silver-based dressing in monolayer cell, tissue explant and animal model. Wound Rep Regen 2007;15:94-104.
18. Rahman GA, Adigun IA, Yusuf IF, Ofoegbu CKP. Wound dressing where there is limitation of choice. Nigerian J Surgery 2006;8(3-4):151-4.
19. Morgan DA. Wounds-What should a dressing formulary include? Hosp Pharm 2002;9:261â€“6.
20. Eccleston GM. Wound dressings. In: Aulton ME. editor. Pharmaceutics: The science of dosage form design. 3rd edition. UK: Churchill Livingstone; 2007. p. 264-71.
21. The annual uk drug tariff. 1988 (Nov), 1998 (May). The Stationary Office. London, UK: The UK Drug Tariff; 2007.
22. Rothe M, Falanga V. Growth factors, their biology and promise in dermatologic disease and tissue repair. Arch Dermatol 1989;125:1390-8.
23. Thomas S. Wounds and wound healing. In: Wound management and dressings. 1st edition. London: Pharmaceutical Press; 1990. p. 1â€“14.
24. Debra JB, Cheri O. Wound healing: Technological innovations and market overview. 1998;2:1-185.
25. Katti DS, Robinson KW, Ko FK, Laurencin CT. Bioresobable nanofiber-based systems for wound healing and drug delivery: Optimisation of fabrication parameters. J Biomed Mater Res Part B 2004;70:286-96.
26. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Delivery Rev 2002;43:3-12.
27. Kietzmann M, Braun M. Effects of the zinc oxide and cod liver oil containing ointment Zincojecol in an animal model of wound healing. Dtsch Tierarztl Wochenschr 2006;113:331-4.
28. Thorn RM, Greenman J, Austin A. An in vitro study of antimicrobial activity and efficacy of iodine-generating hydrogel dressings. J Wound Care 2006;15:305-10.
29. Tsou TL, Tang ST, Huang YC, Wu JR, Young JJ, Wang HJ. Poly (2-hydroxyethyl methacrylate) wound dressing containing ciprofloxacin and its drug release studies. J Mater Sci Mater Med 2002;16:95â€“100.
30. Blanco MD, Garcia O, Gomez C, Sastre RL, Teijon JM. In-vivo drug delivery of 5-fluorouracil using poly (2-hydroxyethyl methacrylate-co-acrylamide) hydrogels. J Pharm Pharmacol 2000;52:1319-25.
31. Blanco MD, Trigo RM, Garcia O, Teijon JM. Controlled release of cytarabine from poly (2-hydroxyethyl methacrylate-co-N-vinyl-2-pyrrolidone. J Biomater Sci Polym Ed 1997;8:709-19.
32. Gottrup F, Jorgensen B, Karlsmark T, Sibbald RG, Rimdeika R, Harding K, et al. Less pain with Biatain-Ibu: Initial findings from a randomised, controlled, doubleblind clinical investigation on painful leg ulcers. Int Wound J 2007;4:24â€“34.
33. Jorgensen B, Friis GJ, Gottrup F. Pain and quality of life for patients with venous leg ulcers: Proof of concept of the efficacy of Biatain-Ibu, a new pain reducing wound dressing. Wound Repair Regen 2006;14:233â€“9.
34. Jorgensen B, Price P, Andersen KE, Gottrup F, Bech-Thomsen N, Scanlon E, et al. The silver-releasing form dressing, Contreet Foam, promotes faster healing of critically colonized venous leg ulcers: A randomised, controlled trial. Int Wound J 2005;2:64â€“73.
35. Rayman G, Rayman A, Baker NR, Jurgeviciene N, Dargis V, Sulcaite R, et al. Sustained silver-releasing dressing in the treatment of diabetic foot ulcers. Br J Nursing 2005;9:109â€“14.
36. Cho YS, Lee JW, Lee JS, Lee JH, Yoon TR, Kuroyanagi Y, et al. Hyaluronic acid and silver sulfadiazine-impregnated polyurethane foams for wound dressing application. J Mater Sci Mater Med 2002;13:861â€“5.
37. Cutting K, White RJ. Maceration of the skin and wound bed 1: Its nature and causes. J Wound Care 2002;11:275â€“8.
38. Chen WYJ, Rogers AA, Lydon MJ. Characterization of biological properties of wound fluid collected during early stages of wound healing. J Invest Dermatol 1992;99:559â€“64.
39. Hareendran A, Bradbury A, Budd J, Geroulakos G, Hobbs R, Kenkre J, et al. Measuring the impact of venous leg ulcers on quality of life. J Wound Care 2005;14:53â€“7.
40. Krasner D. Minimizing factors that impair wound healing: A nursing approach. Ostomy Wound Manag 1995;41:22â€“6.
41. Lee J, Singletary R, Anderson DJ, Bolognesi M, Kaye KS. Surgical site infection in the elderly following orthopaedic surgery: Risk factors and outcomes. J Bone Jt Surg Am Vol 2006;88:1705-12.
42. Hemila H, Douglas RM. Vitamin C and acute respiratory infections. Int J Tuberculosis Lung Dis 1999;3:756-61.
43. Rojas AI, Philips TJ. Patients with chronic leg ulcers show diminished levels of vitamins A and E, carotenes and zinc. Dermatol Surg 1999;25:601-4.
44. Patel GK. The role of nutrition in the management of lower extremity wounds. Int J Lower Extremity Wounds 2005;4:12â€“22.
45. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366:1736-43.
46. Gu F, Amsden B, Neufeld R. Sustained delivery of vascular endothelial growth factor with alginate beads. J Control Release 2004;96:463-72.
47. Schaller M, Laude J, Bodewaldt H, Hamm G, Korting HC. Toxicity and antimicrobial activity of a hydrocolloid dressing containing silver particles in an ex vivo model of cutaneous infection. Skin Pharmacol Physiol 2004;17:31â€“6.
48. Lin SS, Ueng SW, Lee SS, Chan EC, Chen KT, Yang CY, et al. In vitro elution of antibiotic from antibiotic-impregnated biodegradable calcium alginate wound dressing. J Trauma 2000;47:136-41.
49. Meaume S, Vallet D, Morere MN, Teot L. Evaluation of a silver-releasing hydroalginate dressing in chronic wounds with signs of local infection. J Wound Care 2005;14:411â€“9.
50. Luo Y, Kirke KR, Prestwich GD. Crosslinked hyaluronic acid hydrogel films: New biomaterials for drug delivery. J Control Release 2000;69:169â€“84.
51. Yerushalmi N, Arad A, Margalit R. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch Biochem Biophys 1994;313:267â€“73.
52. Defail AJ, Edington HD, Matthews S, Lee WC, Marra KG. Controlled release of bioactive doxorubicin from microspheres embedded within gelatin scaffolds. J Biomed Mater Res 2006;79:954-62.
53. Maeda M, Kadota K, Kajihara M, Sano A, Fujioka K. Sustained release of human growth hormone (hGH) from collagen film and evaluation of effect on wound healing in mice. J Control Release 2001;77:261â€“72.
54. Aoyagi S, Onishi H, Machida Y. Novel chitosan wound dressing loaded with minocycline for the treatment of severe burn wounds. Int J Pharm 2007;330:138â€“45.
55. Mi FL, Wu YB, Shyu SS, Schoung JY, Huang YB, Tsai YH, et al. Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. J Biomed Mater Res 2002;59:438â€“9.
56. Denkbas EB, Ozturk E, Ozdemir N, Kececi K, Agalar C. Norfloxacin-loader chitosan sponges as wound dressing material. J Biomater Appl 2004;18:291â€“303.
57. Ishihara M, Fujita M, Obara K, Hattori H, Nakamura S, Nambu M, et al. Controlled releases of FGF-2 and paclitaxel from chitosan hydrogels and their subsequent effects on wound repair, angiogenesis, and tumour growth. Curr Drug Delivery 2006;3:351â€“8.
58. Sawada Y, Ara M, Yotsuyanagi T, Sone K. Treatment of dermal depth burn wounds with an antimicrobial agent-releasing silicone gel sheet. Burns 1990;16:347â€“52.
59. Sawada Y, Tadashi O, Masazumi K, Kazunobu S, Koichi O, Sasaki J. An evaluation of a new lactic acid polymer drug delivery system: A preliminary report. Br J Plast Surg 1994;47:158-61.
60. Burrell RE, Morris LR. Anti-microbial coating for medical devices. US Patent; 1998.
61. Keuch P, Murdock K, Czap CA, Lennon L. Non-Stingy adhesive hydrophilic gels. US Patent; 1992.
62. Smith DJ, Pulfer S, Shabani M. Polymeric Wound healing accelerators. US Patent; 1996.
63. Suwelack W, Tewes-Schwarzer P, Ecmayer Z. Freeze-dried polysaccharide bio-matrix useful as pharmaceutical or cosmetic carrier. German Patent DE4328329; 1994.
64. Holgaard A. Pharmaceutical preparation. World Patent WO9119480; 1991.
65. Qin Y, Keith D, Nephente W. Dehydrated hydrogels. World patent WO 9739781; 1997.
66. Sakchai W, Churrerat P, Srisagul S. Development and in vitro evaluation of chitosan-eudragit RS 30D composite wound dressings. AAPS Pharm Sci Tech 2006;7:E1â€“E6.
67. Mangala E, Kumar TS, Baskar S, Rao KP. Dev of chitosan/polyvinylalcohol blend membranes as burn dressings. Trends Biomater Artif Organs 2003;17:34-40.
68. Whitaker MJ, Quirk RA, Howdle RA, Shakesheff KM. Growth factor release from tissue engineering scaffolds. J Pharm Pharmacol 2001;53:1427-37.
69. Storie H, Mooney DJ. Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. Adv Drug Delivery Rev 2006;58:500â€“14.
70. Kumar TRS, Bai MV, Krishnan LK. A freeze-dried fibrin disc as a biodegradable drug release matrix. Biologicals 2004;32:49â€“55.
71. Matthews KH, Auffret AD, Humphrey MJ, Stevens HNE, Eccleston GM. Wafers for wound healing. Int J Pharm 2005;289:51â€“62.
72. Hubbell JA. Hydrogel systems for barriers and local drug delivery in the control of wound healing. J Control Release 1996;39:305-13.
73. Shang-Yang L, Shao-Ko C, Run-Chu L. Organic esters of plasticizers affecting the water absorption, adhesive property, glass transition temperature and plasticizer performance of Eudragit acrylic films. J Control Release 2000;68:343-50.
74. Burnett S, Edwardson PAD, Mandley DJ, Velada J. World Patent WO 0234304A1; 2002.
75. Knapp B, Disalvo R. Gel-based cosmetic and wound healing formulation and method. US Patent 2004101515; 2004.
76. Walacavage AJ, Holland JF. Biodegradable wound dressing. US Patent 2004131663; 2004.
77. Matthews KH, Auffret AD, Humphrey MJ, Stevens HNE, Eccleston GM. Gamma irradiation of lyophilised wound healing wafers. Int J Pharm 2006;313:78-86.
78. Dijke P, Iwata KK. Growth factors for wound healing. Biotechnol 1989;7:793â€“8.
79. Hansen SL, Voigt DW, Wiebelhaus P, Paul CN. Using skin replacement products to treat burns and wounds: Advances in Skin & amp. Wound Care 2001;14(1):37â€“45.
80. Pham C, Greenwood J, Cleland H, Woodruff P, Maddern G. Bioengineered skin substitutes for the management of burns: A systematic review. Burns 2007;33(8):946â€“57.
81. Hansbrough JF, Mozingo DW, Kealey GP, Davis M, Gidner A, Gentzkow GD. Clinical trials of a biosynthetic temporary skin replacement, dermagraft-transitional covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. â€ J Burn Care Rehabil 1997;18(1):I43â€“51.
82. Spielvogel RL. A histologic study of Dermagraft-TC in patients burn wounds. J Burn Care Rehabil 1997;18(1):S16â€“S18.
83. Jones I, Currie L, Martin R. A guide to biological skin substitutes. British J Plast Surg 2002;55(3):185â€“93.
84. Falanga V, Margolis D, Alvarez O. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Arch Dermatol 1998;134(3):293-300.
85. Gottlieb ME. Management of complex and pathological wounds with Integra: The Wound Management Manual, McGraw-Hill, New York, NY, USA; 2004. p. 226â€“89.
86. R Goldman. Growth factors and chronic wound healing: past, present, and future. Adv Skin Wound Care 2004;17:24.
87. Bennett SAL, Birnboim HC. Receptor-mediated and protein kinase-dependent growth enhancement of primary human fibroblasts by platelet activating factor. Mol Carcinog 1997;20(4):366-75.
88. Barnes CP, Sell SA, Boland ED, Simpson DG, Bowling GL. Nanofibers technology: Designing the next generation of tissue engineering scaffolds. Adv Drug Delivery Rev 2007;59:1413-33.
89. Gunn J, Zhang M. Polyblend nanofibers for biomedical applications: perspectives and challenges. Trends Biotechnol 2010;28:189-97.
90. Zahedi P, Rezaeian I, Ranaei-Siadat SO, Jafari SH, Supaphol P. A review on wound dressings with an emphasis on electro spunnanofibrous polymeric bandages. Polym Adv Technol 2010;21:77-95.
91. Singer AJ, Dagum AB. Current management of acute cutaneous wounds. N Engl J Med 2008;359:1037.
92. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010;33(5):998-1003.
93. Abidia A, Laden G, Kuhan G. The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomized-controlled trial. Eur J Vascular Endovascular Surg 2003;25(6):513â€“8.